Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue (2011 - 2017)
Supernus Pharmaceuticals (SUPN) posted quarterly Non-Current Deffered Revenue of $1.1 million for Q4 2017, down 23.45% year-over-year from $1.5 million in Q4 2016, and down 5.9% on a QoQ basis from $1.2 million in Q3 2017.
Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue (2011 - 2017) Analysis & Trends
Supernus Pharmaceuticals has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $1.1 million in Q4 2017.
- Non-Current Deffered Revenue for Q4 2017 came in at $1.1 million, down 23.45% year-over-year; the trailing twelve-month figure through Dec 2017 was $1.1 million (down 23.45% YoY), and the FY2017 annual result was $1.1 million, down 23.45% from the prior year.
- Non-Current Deffered Revenue retreated to $1.1 million in Q4 2017, from $1.2 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $1.7 million in Q1 2016 and troughed at $738000.0 in Q2 2013.
- A 5-year average of $1.3 million and a median of $1.3 million in 2014 frame the typical range for Non-Current Deffered Revenue.
- The widest annual swing landed in 2013, when Non-Current Deffered Revenue surged 358.58%; it then declined 23.45% in 2017.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $1.4 million in 2013, then retreated by 10.09% to $1.3 million in 2014, then advanced by 9.11% to $1.4 million in 2015, then increased by 7.99% to $1.5 million in 2016, then decreased by 23.45% to $1.1 million in 2017.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.1 million in Q4 2017, $1.2 million in Q3 2017, and $1.3 million in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 1.15 Mn |
| Sep 30, 2017 | 1.22 Mn |
| Jun 30, 2017 | 1.29 Mn |
| Mar 31, 2017 | 1.37 Mn |
| Dec 31, 2016 | 1.50 Mn |
| Sep 30, 2016 | 1.55 Mn |
| Jun 30, 2016 | 1.61 Mn |
| Mar 31, 2016 | 1.66 Mn |
| Dec 31, 2015 | 1.39 Mn |
| Sep 30, 2015 | 1.17 Mn |
| Jun 30, 2015 | 1.20 Mn |
| Mar 31, 2015 | 1.24 Mn |
| Dec 31, 2014 | 1.27 Mn |
| Sep 30, 2014 | 1.31 Mn |
| Jun 30, 2014 | 1.35 Mn |
| Mar 31, 2014 | 1.38 Mn |
| Dec 31, 2013 | 1.42 Mn |
| Sep 30, 2013 | 1.45 Mn |
| Jun 30, 2013 | 738,000.00 |
| Mar 31, 2013 | 774,000.00 |